ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,350 GBX | +0.73% |
|
+4.57% | +7.15% |
| 04:14pm | Angle plc to Develop New Cancer Assay in Deal with AstraZeneca | MT |
| 01:38pm | ASTRAZENECA : Bernstein reiterates its Buy rating | ZD |
Financials (USD)
| Sales 2024 * | 50.76B | Sales 2025 * | 54.29B | Capitalization | 217B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.71B | Net income 2025 * | 10.26B | EV / Sales 2024 * | 4.67 x |
| Net Debt 2024 * | 19.95B | Net Debt 2025 * | 13.42B | EV / Sales 2025 * | 4.25 x |
| P/E ratio 2024 * |
25.6
x | P/E ratio 2025 * |
21.6
x | Employees | 89,900 |
| Yield 2024 * |
2.21% | Yield 2025 * |
2.33% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +0.81% | ||
| 1 week | +4.55% | ||
| Current month | +6.35% | ||
| 1 month | +9.26% | ||
| 3 months | +8.63% | ||
| 6 months | +8.79% | ||
| Current year | +7.13% |
1 week
10 764.00
11 412.00
1 month
10 314.0011 412.00
Current year
9 461.0011 412.00
1 year
9 461.0012 348.00
3 years
7 392.0012 392.00
5 years
5 626.0012 392.00
10 years
3 680.0012 392.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +12.53% | ||
| 5.17% | 18 M€ | +4.24% | - | |
| 4.89% | 776 M€ | +8.16% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 11,356 | +0.78% | 1 146 386 |
| 24-04-23 | 11,268 | +0.16% | 3,561,073 |
| 24-04-22 | 11,250 | +2.78% | 3,448,159 |
| 24-04-19 | 10,946 | +0.29% | 1,407,714 |
| 24-04-18 | 10,914 | +0.48% | 2,446,630 |
Delayed Quote London S.E., April 24, 2024 at 11:02 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
140.2
USD
Average target price
161.5
USD
Spread / Average Target
+15.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.13% | 217B | |
| +25.92% | 672B | |
| +25.87% | 570B | |
| -5.94% | 360B | |
| +15.68% | 321B | |
| +8.47% | 300B | |
| -9.16% | 204B | |
| +5.11% | 199B | |
| -9.00% | 149B | |
| -5.00% | 147B |
- Stock Market
- Equities
- AZN Stock
